COPD
COPD
12/06/2017
The FDA has approved a new option for the long-term maintenance treatment of airflow obstruction in individuals with chronic obstructive pulmonary disease.
12/06/2017
COPD
COPD
12/06/2017
The FDA has approved a new option for the long-term maintenance treatment of airflow obstruction in individuals with chronic obstructive pulmonary disease.
12/06/2017
Diabetes Q&A
Diabetes Q&A
12/05/2017
The US Food and Drug Administration recently approved a new glucagon-like peptide-1 receptor antagonist for improving glycemic control in patients with type 2 diabetes.
12/05/2017
Diabetes Q&A
Diabetes Q&A
12/05/2017
The US Food and Drug Administration recently approved a new glucagon-like peptide-1 receptor antagonist for improving glycemic control in patients with type 2 diabetes.
12/05/2017
Diabetes Q&A
Diabetes Q&A
12/05/2017
The US Food and Drug Administration recently approved a new glucagon-like peptide-1 receptor antagonist for improving glycemic control in patients with type 2 diabetes.
12/05/2017
Psoriasis
Psoriasis
12/04/2017
The FDA has approved a new indication for a drug previously approved for the treatment of adults with moderate-to-severe plaque psoriasis.
12/04/2017
Psoriasis
Psoriasis
12/04/2017
The FDA has approved a new indication for a drug previously approved for the treatment of adults with moderate-to-severe plaque psoriasis.
12/04/2017
Allergic Disorders
Allergic Disorders
11/21/2017
The FDA has approved a new option for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants and young children.
11/21/2017
HIV
HIV
11/21/2017
After 2 clinical trials demonstrated its safety and efficacy, the US Food and Drug Administration approved the first complete HIV treatment regimen containing only 2 drugs.
11/21/2017
hemophilia
hemophilia
11/16/2017
After clinical trials demonstrated its efficacy, the US Food and Drug Administration approved a new treatment option for patients with hemophilia A who have Factor VIII inhibitors.
11/16/2017